Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02223819 · ClinicalTrials.gov registry record · Phase 2
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
A Phase 2 study of Uveal Melanoma, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 4
- Study locations
NCT02223819 is a Phase 2 study of Uveal Melanoma that has completed, run by Columbia University. The registered enrollment target is 34 participants, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02223819, a Phase 2 study of Uveal Melanoma, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in this patient population.
Conditions Studied
Interventions
- DRUG Crizotinib
Study Locations (4)
New York
- Columbia Univeristy Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02223819
The ClinicalTrials.gov registry entry for NCT02223819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (76% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Crizotinib is the first listed.
NCT02223819 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT02223819 about?
NCT02223819 is a clinical study titled "Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy". The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in th...
What is the current status of trial NCT02223819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2015-03. Estimated completion is 2019-07-03.
What conditions does trial NCT02223819 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT02223819?
The interventions under investigation include: Crizotinib (DRUG).
Who is sponsoring clinical trial NCT02223819?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02223819 being conducted?
This trial has 4 study locations across Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.